BERLIN--(BUSINESS WIRE)--Nov 14, 2025--
ESMO AI & Digital Health 2025 - Massive Bio today introduced Reticulum Nexus, the company’s most significant technological leap to date: a patient-centric, multi-agent platform engineered to coordinate the full oncology journey, from first contact to last-mile enrollment, across networks operating at global scale.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251112162820/en/
In an environment where clinical trial access has long been constrained by fragmented data pipelines, site-centric processes, and human-heavy workflows, Reticulum Nexus establishes a unified operating fabric. This next-generation system integrates clinical and operational intelligence to match, enroll, and collect outcomes to build more powerful advanced analytics.
The company’s most recent announcements include:
“Most systems optimize a single node,” said Selin Kurnaz, PhD, Cofounder & CEO. “Reticulum Nexus will help bring in the world’s first scalable patient journey, and paired with the enablement of AI agents.”
“ Moravec’s Paradox shows us the boundary between repetitive and contextual work,” said Arturo Loaiza-Bonilla, MD, Cofounder & Chief Medical AI Officer. “With Reticulum Nexus, multi-agent, contextual AI handles the operational load so clinicians can focus on human care. Dr. Arturo AI already supports thousands of patients; we can now safely scale to millions.”
“Radiant Core is the control plane that makes agentic AI dependable at production scale,” added Çağatay Çulcuoğlu, Cofounder, CTO & COO. “SYNERGYAI OS is the routing fabric connecting every workflow. Together, they deliver interoperability, auditability, and real-world performance from day one.”
Inside Reticulum Nexus
Radiant Core - the control plane focused on data quality, compliance, and agent behavior.
SYNERGYAI OS - the multi-agent operating system
Interoperable Architecture - native FHIR/mCODE integration, governance designed for regulated environments (GDPR, HIPAA).
Modules Available at Launch
About Massive Bio
Massive Bio, co-founded by Selin Kurnaz, Arturo Loaiza-Bonilla, and Çağatay Çulcuoğlu, transforms the pharmaceutical value chain with AI-driven solutions. As an AI-enabled real-world data company, Massive Bio streamlines patient journeys, improves access to cutting-edge treatments, and optimizes clinical trial operations across 17 countries. A founding member of the CancerX public-private partnership and participant in the White House Cancer Moonshot initiative, the company continues to lead the way in ethical AI and data-driven innovation.
For more information, visit www.massivebio.com.
Reticulum Nexus: Massive Bio’s new AI-driven multi-agent platform supporting every step of the patient journey.
